Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2 -Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.
Yusuke NaritaTakuya YoshimotoTomoyuki NamaiTakashi AsakawaSatoe KawakamiCraig Gower-PageIrmarie Reyes-RiveraArisha PatelYoshiaki NakamuraPublished in: JCO clinical cancer informatics (2022)
Despite a small sample size, these findings suggest that PER-HER could have a potential OS benefit for this population.